[Use of zoledronic acid for high risk prostate cancer patients].
Rexer
H
H
MeckEvidence, Schwartz. AUO@MeckEvidence.de
D000818:Animals; D001859:Bone Neoplasms / Q000517:prevention & control / Q000556:secondary*; D004164:Diphosphonates / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005060:Europe; D006801:Humans; D006934:Hypercalcemia / Q000517:prevention & control; D007093:Imidazoles / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid